Bristol-Myers Squibb
American pharmaceutical company
BMY NYSE
ISIN US1101221083 SEC CIK 14272 LEI HLYYNH7UQUORYSJQCN42
Follow Bristol-Myers Squibb
Weekly email: filings, results
Revenue, last quarter
$13.1B
+6.9% vs same quarter last year
Net income
$2.2B
−1.8% vs same quarter last year
EPS, diluted
$1.05
−2.8% vs same quarter last year
Operating cash flow
$4.2B
−33.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $48.2B | $7.1B |
| FY24 | $48.3B | −$8.9B |
| FY23 | $45B | $8B |
| FY22 | $46.2B | $6.3B |
| FY21 | $46.4B | $7B |
| FY20 | $42.5B | −$9B |
| FY19 | $26.1B | $3.4B |
| FY18 | $22.6B | $4.9B |
| FY17 | $20.8B | $1B |
| FY16 | $19.4B | $4.5B |
| FY15 | $16.6B | $1.6B |
| FY14 | $15.9B | $2B |
| FY13 | $16.4B | $2.6B |
| FY12 | $17.6B | $2B |
| FY11 | $21.2B | $3.7B |
- Gross margin
- Net margin
Show the numbers
| Year | Gross margin | Net margin |
|---|---|---|
| FY25 | 71.1% | 14.6% |
| FY24 | 71.1% | −18.5% |
| FY23 | 76.2% | 17.8% |
| FY22 | 78% | 13.7% |
| FY21 | 78.6% | 15.1% |
| FY20 | 72.3% | −21.2% |
| FY19 | 69.1% | 13.2% |
| FY18 | 71.3% | 21.8% |
| FY17 | 70.7% | 4.8% |
| FY16 | 74.5% | 22.9% |
| FY15 | 76.4% | 9.5% |
| FY14 | 75.2% | 12.6% |
| FY13 | 71.8% | 15.6% |
| FY12 | 73.8% | 11.1% |
| FY11 | 73.6% | 17.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $12.8B |
| FY24 | $13.9B |
| FY23 | $12.7B |
| FY22 | $11.9B |
| FY21 | $15.2B |
| FY20 | $13.3B |
| FY19 | $7.4B |
| FY18 | $6.1B |
| FY17 | $4.2B |
| FY16 | $1.8B |
| FY15 | $1.3B |
| FY14 | $2.6B |
| FY13 | $3B |
| FY12 | $6.4B |
| FY11 | $4.5B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $5B | $0 |
| FY24 | $4.9B | $0 |
| FY23 | $4.7B | $5.2B |
| FY22 | $4.6B | $8B |
| FY21 | $4.4B | $6.3B |
| FY20 | $4.1B | $1.5B |
| FY19 | $2.7B | $7.3B |
| FY18 | $2.6B | $320M |
| FY17 | $2.6B | $2.5B |
| FY16 | $2.5B | $231M |
| FY15 | $2.5B | - |
| FY14 | $2.4B | - |
| FY13 | $2.3B | $433M |
| FY12 | $2.3B | $2.4B |
| FY11 | $2.3B | $1.2B |
- Bristol-Myers Squibb
- Healthcare median
Show the numbers
| Year | Bristol-Myers Squibb | Healthcare median |
|---|---|---|
| FY25 | 14.6% | −30.6% |
| FY24 | −18.5% | −47% |
| FY23 | 17.8% | −58% |
| FY22 | 13.7% | −80.4% |
| FY21 | 15.1% | −71.9% |
| FY20 | −21.2% | −62.2% |
| FY19 | 13.2% | −46.3% |
| FY18 | 21.8% | −49.6% |
| FY17 | 4.8% | −45.9% |
| FY16 | 22.9% | −36% |
| FY15 | 9.5% | −38.4% |
| FY14 | 12.6% | −35.5% |
| FY13 | 15.6% | −37.1% |
| FY12 | 11.1% | −29.1% |
| FY11 | 17.5% | −27.9% |